Table 2.

Key immunotherapy trials

Drug name	Trial number	Phase	Comments
Camrelizumab^[72]	NCT02989922	II	Response rate 14%. Median OS 14.4 months (predominantly HBV-positive patients)
Tislelizumab	NCT02412773	III	Active recruiting
Pembrolizumab (Keynote 937)	NCT03062358	III	Active recruiting in Asia
Pembrolizumab (Keynote 394)	NCT03062358	III	Active accrual in Asia
Nivolumab (Checkmate 9DX)	NCT03383458	III	Currently recruiting
Nivolumab and Ipilimumab	NCT03222076	II	Currently recruiting
Cemiplimab^[73]	NCT03916627	II	Currently recruiting
Tislelizumib	NCT03412773	III	Results pending
Durvalumab with tremelimumab and ablation^[75]	NCT02821754	I/II	Response rate 20% Median PFS 7.8 months
Durvalumab with tremelimumab (HIMALAYA )	NCT03298451	III	Currently recruiting

PFS: progression-free survival; OS: overall survival